Search
Amolimogene bepiplasmid
go.drugbank.com/drugs/DB04904InvestigationalAmolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV).
Pegvisomant
go.drugbank.com/drugs/DB00082ApprovedInvestigationalPegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediat...
Kitasamycin
go.drugbank.com/drugs/DB09309ExperimentalKitasamycin is a macrolide antibiotic derived from <em>Streptomyces kitasatoensis</em>.
Fosifloxuridine nafalbenamide
go.drugbank.com/drugs/DB14859InvestigationalFosifloxuridine nafalbenamide is under investigation in clinical trial NCT03428958 (A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment).
Ieramilimab
go.drugbank.com/drugs/DB16419InvestigationalIeramilimab is under investigation in clinical trial NCT02460224 (Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.).
Neisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB15680ApprovedInvestigationalNeisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB15681ApprovedInvestigationalProducts: NeisVac-C Injektionssuspension in einer FertigspritzeOfloxacin
go.drugbank.com/drugs/DB01165ApprovedInvestigationalA synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Quavonlimab
go.drugbank.com/drugs/DB16422InvestigationalQuavonlimab is under investigation in clinical trial NCT03179436 (Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)).
AP5346
go.drugbank.com/drugs/DB04992InvestigationalAP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. It is being pursued by Access Pharmaceuticals, Inc.